Newly Published
Editorial Views  |   April 2018
Immunotherapy for Sepsis: A Good Idea or Another Dead End?
Author Notes
  • From the Keenan Research Centre for Biomedical Research, St. Michael’s Hospital, Toronto, Canada; and the Interdepartmental Division of Critical Care, Department of Medicine, University of Toronto, Toronto, Canada.
  • Accepted for publication March 20, 2018.
    Accepted for publication March 20, 2018.×
  • Research Support: Dr. Lee is the Canada Research Chair in Mechanisms of Endothelial Permeability. Work in his lab is funded by the Canadian Institutes of Health Research, Ottawa, Canada (grant No. MOP 130564) and supported by the Canada Foundation for Innovation, Ottawa, Canada (grant No. 34769).
    Research Support: Dr. Lee is the Canada Research Chair in Mechanisms of Endothelial Permeability. Work in his lab is funded by the Canadian Institutes of Health Research, Ottawa, Canada (grant No. MOP 130564) and supported by the Canada Foundation for Innovation, Ottawa, Canada (grant No. 34769).×
  • Competing Interests: Dr. Lee is a coinventor on a patent for a Tie2 agonist (Vasculotide) in the treatment of influenza and serves on the scientific advisory board for Vasomune (Toronto, Canada).
    Competing Interests: Dr. Lee is a coinventor on a patent for a Tie2 agonist (Vasculotide) in the treatment of influenza and serves on the scientific advisory board for Vasomune (Toronto, Canada).×
  • Correspondence: Address correspondence to Dr. Lee: leew@smh.ca
Article Information
Editorial Views / Critical Care
Editorial Views   |   April 2018
Immunotherapy for Sepsis: A Good Idea or Another Dead End?
Anesthesiology Newly Published on April 19, 2018. doi:10.1097/ALN.0000000000002237
Anesthesiology Newly Published on April 19, 2018. doi:10.1097/ALN.0000000000002237
This content is PDF only. Please click on the PDF icon to access.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large